Technology Platform
DLong MedTech’s technology platform brings together purpose-built balloon catheter design, drug-coated balloon technology, vascular simulation, and quality-driven product development.
The platform supports DLong’s current focus on pulmonary artery stenosis, chronic thromboembolic pulmonary hypertension, and complex coronary disease, while providing a foundation for future pan-vascular applications.
Balloon Catheter Engineering
Designed to support lesion access, controlled dilation, deliverability, trackability, and durability in complex pulmonary and coronary anatomy.
Drug-Coated Balloon Technology
Combines mechanical dilation with localized paclitaxel delivery to support implant-free or stent-free therapy in selected vascular indications.
Vascular Simulation & Training
Supports device evaluation, product demonstration, physician education, and hands-on catheter-based intervention training.
Strategic Roadmap
DLong MedTech is advancing purpose-built interventional balloon technologies for chronic thromboembolic pulmonary hypertension, pulmonary artery stenosis, coronary small-vessel disease, and coronary bifurcation lesions. In the near term, the company is focused on progressing its lead products through clinical evaluation, supporting regulatory submissions, preparing for FDA registration, and establishing a strong foundation for product launch and market adoption.
Long term, DLong MedTech is building a pan-vascular interventional technology platform powered by balloon catheter engineering, drug-coated balloon technology, vascular simulation, and quality-driven product development. By expanding from pulmonary and coronary intervention into broader vascular applications, DLong is positioned to develop a scalable pipeline of minimally invasive, vessel-preserving therapies for complex vascular diseases.
With a focused product strategy, strong technology foundation, and clear clinical direction, DLong MedTech aims to become a differentiated leader in next-generation vascular intervention, delivering innovative solutions that address important unmet needs across pulmonary, coronary, and broader vascular markets.